Israeli pharmaceutical company Compugen, which develops genomics-based drug and diagnostic discovery tools, has sold its controlling stake in its subsidiary Keddem Bioscience. The acquisition, estimated to worth $15 million, was made by a privately owned US based investment company.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

People With Autism Experience Higher Intensity Pain
January 30, 2023

Israeli Innovation At New Bahraini Hospital
January 30, 2023

US Car Giant Signs Up For AI Vehicle Inspections
January 29, 2023

Considerate Partners Are Less Likely To Cheat
January 29, 2023
Facebook comments